BRPI0809600A2 - vírus atenuado útil para vacinas - Google Patents
vírus atenuado útil para vacinasInfo
- Publication number
- BRPI0809600A2 BRPI0809600A2 BRPI0809600A BRPI0809600A BRPI0809600A2 BR PI0809600 A2 BRPI0809600 A2 BR PI0809600A2 BR PI0809600 A BRPI0809600 A BR PI0809600A BR PI0809600 A BRPI0809600 A BR PI0809600A BR PI0809600 A2 BRPI0809600 A2 BR PI0809600A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccines
- attenuated virus
- virus useful
- useful
- attenuated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A61K39/13—Poliovirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12361—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
- C12N2740/15061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16161—Methods of inactivation or attenuation
- C12N2760/16162—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24161—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32061—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32621—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32661—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32661—Methods of inactivation or attenuation
- C12N2770/32662—Methods of inactivation or attenuation by genetic engineering
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32611—Poliovirus
- C12N2770/32671—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32721—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32761—Methods of inactivation or attenuation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/32011—Picornaviridae
- C12N2770/32711—Rhinovirus
- C12N2770/32761—Methods of inactivation or attenuation
- C12N2770/32762—Methods of inactivation or attenuation by genetic engineering
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90938907P | 2007-03-30 | 2007-03-30 | |
US60/909,389 | 2007-03-30 | ||
US6866608P | 2008-03-07 | 2008-03-07 | |
US61/068,666 | 2008-03-07 | ||
PCT/US2008/058952 WO2008121992A2 (en) | 2007-03-30 | 2008-03-31 | Attenuated viruses useful for vaccines |
Publications (2)
Publication Number | Publication Date |
---|---|
BRPI0809600A2 true BRPI0809600A2 (pt) | 2016-07-12 |
BRPI0809600B1 BRPI0809600B1 (pt) | 2023-01-24 |
Family
ID=39808891
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0809600-7A BRPI0809600B1 (pt) | 2007-03-30 | 2008-03-31 | Vírus atenuado útil para vacinas |
Country Status (13)
Country | Link |
---|---|
US (4) | US9476032B2 (pt) |
EP (3) | EP2139515B2 (pt) |
JP (2) | JP5733976B2 (pt) |
KR (1) | KR101621100B1 (pt) |
CN (1) | CN103476425B (pt) |
AU (1) | AU2008232491B2 (pt) |
BR (1) | BRPI0809600B1 (pt) |
CA (1) | CA2682089C (pt) |
DK (1) | DK2139515T4 (pt) |
HR (1) | HRP20181319T4 (pt) |
MX (2) | MX349825B (pt) |
PL (1) | PL2139515T5 (pt) |
WO (1) | WO2008121992A2 (pt) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0809600B1 (pt) | 2007-03-30 | 2023-01-24 | The Research Foundation Of State University Of New York | Vírus atenuado útil para vacinas |
WO2010039649A2 (en) * | 2008-10-03 | 2010-04-08 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Flavivirus-based system for production of hepatitis c virus (hcv) |
WO2010088552A1 (en) | 2009-01-30 | 2010-08-05 | The Board Of Regents For Oklahoma State University | Immunogenic compositions, vaccines and diagnostics based on canine distemper viruses circulating in north american dogs |
EP2403527A4 (en) * | 2009-03-06 | 2012-11-14 | Sinai School Medicine | LIVELY WEAKED INFLUENZA VIRUS VACCINES WITH MICRORNA REACTION ELEMENTS |
TW201125984A (en) * | 2009-10-09 | 2011-08-01 | Univ New York State Res Found | Attenuated influenza viruses and vaccines |
EP2490268A1 (en) * | 2011-02-03 | 2012-08-22 | Imec | Method for fabricating photovoltaic cells |
US20140302077A1 (en) * | 2011-09-02 | 2014-10-09 | Westfaelische Wilhelms-Universitaet Munester | Live attenuated influenza virus |
BR112014014654A2 (pt) * | 2011-12-16 | 2019-09-24 | Univ New York State Res Found | novo poliovirus atenuado: pv-1 mono-cre-x |
US20140363469A1 (en) * | 2012-01-19 | 2014-12-11 | Alnylam Pharmaceuticals, Inc. | Viral attenuation and vaccine production |
CA2900713A1 (en) * | 2013-02-08 | 2014-08-14 | Steffen Mueller | Attenuation of human respiratory syncytial virus by genome scale codon-pair deoptimization |
US10232032B2 (en) * | 2013-03-14 | 2019-03-19 | Emory University | Recombinant RSV with silent mutations, vaccines, and methods related thereto |
EP2969005B1 (en) | 2013-03-15 | 2019-10-16 | The Research Foundation for The State University of New York | Attenuated influenza viruses and vaccines |
CN104056276B (zh) * | 2013-03-20 | 2017-05-10 | 上海生物制品研究所有限责任公司 | 一种流感病毒减毒活疫苗及其制备方法 |
CN104419687B (zh) * | 2013-09-03 | 2017-03-15 | 中国农业大学 | 重组PRRS病毒HV‑nsp29及其应用 |
MX2017002949A (es) | 2014-09-05 | 2017-12-14 | Univ New York State Res Found | Arbovirus recodificado y vacunas. |
US10731227B2 (en) | 2014-12-12 | 2020-08-04 | The Trustees Of The University Of Pennsylvania | Compositions, kits, and methods to detect HIV virus |
WO2017099801A1 (en) * | 2015-12-11 | 2017-06-15 | The Trustees Of The University Of Pennsylvania | Compositions, kits, and methods to detect hiv virus |
EP3050962A1 (en) | 2015-01-28 | 2016-08-03 | Institut Pasteur | RNA virus attenuation by alteration of mutational robustness and sequence space |
WO2016192670A1 (en) * | 2015-06-04 | 2016-12-08 | The University Of Hong Kong | Live-attenuated virus and methods of production and use |
WO2017056094A1 (en) * | 2015-09-30 | 2017-04-06 | Ramot At Tel-Aviv University Ltd. | Attenuated virus mutated at sites of evolutionarily conserved rna structure |
SG11201803581VA (en) | 2015-10-29 | 2018-05-30 | Univ Emory | Chimeric RSV, Immunogenic Compositions, and Methods of Use |
CN105821009B (zh) * | 2016-04-05 | 2019-07-26 | 中国人民解放军第三〇二医院 | 靶向肝癌溶瘤流感病毒的构建及其应用 |
WO2017218727A1 (en) | 2016-06-15 | 2017-12-21 | President And Fellows Of Harvard College | Methods for rule-based genome design |
EP3488239A1 (en) * | 2016-07-22 | 2019-05-29 | Verily Life Sciences LLC | Quantitative massively parallel proteomics |
US11149255B2 (en) * | 2016-09-06 | 2021-10-19 | Bioventures, Llc | Compositions and methods for generating reversion free attenuated and/or replication incompetent vaccine vectors |
CN106650307B (zh) * | 2016-09-21 | 2019-04-05 | 武汉伯远生物科技有限公司 | 一种基于密码子对使用频度的基因密码子优化方法 |
WO2018057950A1 (en) | 2016-09-23 | 2018-03-29 | The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Vaccine candidates for human respiratory syncytial virus (rsv) having attenuated phenotypes |
CN106520832B (zh) * | 2016-11-17 | 2020-02-18 | 新乡医学院 | 双顺反子表达载体、表达系统、制备方法及应用 |
JP2020502080A (ja) * | 2016-11-30 | 2020-01-23 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 弱毒ブタインフルエンザワクチン並びにその作製および使用方法 |
AR111770A1 (es) | 2017-05-05 | 2019-08-21 | Elanco Us Inc | Vacuna para enfermedad respiratoria bovina |
BR112020000802A2 (pt) * | 2017-07-17 | 2020-07-21 | Glaxosmithkline Biologicals S.A. | construto baseado em ácido nucleico, vetor, moléculas de rna autoamplificável e de dna, composição, método para induzir uma resposta imune contra uma doença causada por um lyssavírus, processo para produzir uma vacina baseada em rna, e, uso do construto, do vetor, da molécula de rna autoamplificável ou de uma composição. |
MX2020006530A (es) * | 2017-12-22 | 2020-10-15 | Codagenix Inc | Virus recombinante con region desoptimizada de par de codones y usos del mismo para el tratamiento de cancer. |
CN108586608A (zh) * | 2018-04-13 | 2018-09-28 | 四川农业大学 | 一种dhav-1 2c蛋白多克隆抗体、重组融合蛋白及其制备方法 |
CN109504662B (zh) * | 2018-11-09 | 2022-06-10 | 浙江天元生物药业有限公司 | 一种柯萨奇病毒减毒株及其应用 |
EP3893927A1 (en) | 2018-12-14 | 2021-10-20 | GlaxoSmithKline Biologicals S.A. | Heterologous prime boost vaccine compositions and methods |
IL295112A (en) * | 2020-01-28 | 2022-09-01 | Codagenix Inc | Suboptimal polynucleotides and 2-cov-sars viruses and their uses |
CN111269895B (zh) * | 2020-02-03 | 2022-09-27 | 广州医科大学 | 甲型流感病毒减毒株及其作为骨架病毒和疫苗的应用 |
CN111321125B (zh) * | 2020-02-03 | 2022-07-19 | 广州医科大学 | 重组流感病毒及其在疫苗中的应用 |
US20230122776A1 (en) * | 2020-03-27 | 2023-04-20 | Johannes Reinmüller | Antiviral agent |
CN111481663B (zh) * | 2020-04-09 | 2022-12-09 | 广州医科大学 | 一种流感病毒活疫苗及其制备方法 |
WO2021216743A2 (en) * | 2020-04-21 | 2021-10-28 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
PE20230833A1 (es) * | 2020-05-27 | 2023-05-19 | Us Agriculture | Cepas vivas atenuadas de la fiebre aftosa modificadas por desoptimizacion y usos de estas |
EP4179074A1 (en) * | 2020-07-07 | 2023-05-17 | Codagenix Inc. | Method of producing modified virus genomes and producing modified viruses |
EP4181956A1 (en) * | 2020-07-16 | 2023-05-24 | Griffith University | Live-attenuated virus vaccine |
US20240018609A1 (en) * | 2020-08-19 | 2024-01-18 | City Of Hope | Lamp detection of sars-cov-2 in saliva for the rapid diagnosis of covid-19 |
CN112662633A (zh) * | 2020-12-28 | 2021-04-16 | 中国水产科学研究院珠江水产研究所 | II型草鱼呼肠孤病毒冷适应株GCRV-GD108ca及其应用 |
WO2022269248A1 (en) * | 2021-06-23 | 2022-12-29 | University Of Lancaster | Virus attenuation |
US20230274791A1 (en) * | 2021-11-29 | 2023-08-31 | The Chinese University Of Hong Kong | Codon de-optimization or optimization using genetic architecture |
WO2024036331A2 (en) * | 2022-08-12 | 2024-02-15 | Fred Hutchinson Cancer Center | Barcoded influenza viruses and mutational scanning libraries including the same |
CN117153270B (zh) * | 2023-10-30 | 2024-02-02 | 吉林华瑞基因科技有限公司 | 一种基因二代测序数据处理方法 |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004147A1 (en) | 1993-08-02 | 1995-02-09 | Chiron Corp | Recombinant constructs using replacement sequences in hypervariable regions |
US6352842B1 (en) | 1995-12-07 | 2002-03-05 | Diversa Corporation | Exonucease-mediated gene assembly in directed evolution |
US6171820B1 (en) | 1995-12-07 | 2001-01-09 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6764835B2 (en) | 1995-12-07 | 2004-07-20 | Diversa Corporation | Saturation mutageneis in directed evolution |
WO2000053744A2 (en) | 1999-03-09 | 2000-09-14 | Diversa Corporation | End selection in directed evolution |
US20040023327A1 (en) | 1995-12-07 | 2004-02-05 | Short Jay M. | End selection in directed evolution |
US6537776B1 (en) | 1999-06-14 | 2003-03-25 | Diversa Corporation | Synthetic ligation reassembly in directed evolution |
US6562594B1 (en) | 1999-09-29 | 2003-05-13 | Diversa Corporation | Saturation mutagenesis in directed evolution |
US6238884B1 (en) | 1995-12-07 | 2001-05-29 | Diversa Corporation | End selection in directed evolution |
CA2257823A1 (en) | 1996-07-15 | 1998-01-22 | Government Of The United States Of America As Represented By The Secreta Ry Of The Department Of Health And Human Services National Institutes Of | Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences |
GB9705669D0 (en) † | 1997-03-19 | 1997-05-07 | British Tech Group | Attenuated polioviruses |
US6410023B1 (en) | 1997-05-23 | 2002-06-25 | United States Of America | Recombinant parainfluenza virus vaccines attenuated by deletion or ablation of a non-essential gene |
CA2268737A1 (en) * | 1997-08-07 | 1999-02-18 | Altwell Biotech. Inc. | Replication-competent recombinant sabin type 1 strain of poliovirus |
EP1690868A1 (en) | 1997-10-31 | 2006-08-16 | Maxygen, Inc. | Modification of virus tropism and host range by viral genome shuffling |
GB9817082D0 (en) † | 1998-08-06 | 1998-10-07 | Btg Int Ltd | Attenuated poliovirus vaccine |
JP2002537758A (ja) | 1998-09-29 | 2002-11-12 | マキシジェン, インコーポレイテッド | コドン変更された遺伝子のシャッフリング |
CA2329122A1 (en) | 1999-03-26 | 2000-10-05 | Diversa Corporation | Exonuclease-mediated nucleic acid reassembly in directed evolution |
CA2291367A1 (en) * | 1999-12-06 | 2001-06-06 | Isabelle Henry | Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof |
US20020076415A1 (en) | 1999-12-14 | 2002-06-20 | Jing-Hsiung Ou | Hepatitis C virus gene products |
AUPQ776100A0 (en) | 2000-05-26 | 2000-06-15 | Australian National University, The | Synthetic molecules and uses therefor |
GB0017990D0 (en) | 2000-07-21 | 2000-09-13 | Glaxo Group Ltd | Papilloma virus sequences |
CZ2003180A3 (cs) | 2000-07-21 | 2003-08-13 | Glaxo Group Limited | Papilomavirové sekvence s optimalizovanými kodony |
US20050124010A1 (en) | 2000-09-30 | 2005-06-09 | Short Jay M. | Whole cell engineering by mutagenizing a substantial portion of a starting genome combining mutations and optionally repeating |
US20030041354A1 (en) | 2000-10-17 | 2003-02-27 | Novozymes A/S | Transgenic plants |
ATE403152T1 (de) | 2000-10-17 | 2008-08-15 | Besst Test Aps | Test zum direkten nachweisen einer biologischen zelle in einer körperflüssigkeitsprobe |
WO2002095363A2 (en) * | 2001-05-25 | 2002-11-28 | Tao Biosciences, Llc | Methods for attenuation of virulence in bacteria |
PT2311848E (pt) | 2002-12-23 | 2013-10-03 | Vical Inc | Vacinas à base de polinucleótido optimizadas por codão contra a infecção do citomegalovírus humano |
WO2005014626A2 (en) | 2003-02-28 | 2005-02-17 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Recombinant human metapneumovirus and its use |
WO2005024012A1 (en) | 2003-09-11 | 2005-03-17 | Novozymes A/S | Increased expression of a modified polypeptide |
DK1735451T3 (da) | 2004-04-07 | 2010-03-08 | Novozymes As | Muteret prokaryot celle med høje secerneringsniveauer |
EP2644696B1 (en) | 2004-05-24 | 2015-07-15 | MedImmune, LLC | Method of increasing replication of a reassortant influenza virus in eggs. |
AU2005287395A1 (en) | 2004-07-02 | 2006-03-30 | Henry L. Niman | Copy choice recombination and uses thereof |
CA2574511A1 (en) | 2004-07-20 | 2006-02-16 | Novozymes, Inc. | Methods of producing mutant polynucleotides |
ATE445010T1 (de) | 2004-08-03 | 2009-10-15 | Univ California | Stellenspezifisches system zur erstellung vielfältiger proteinsequenzen |
EP3312272B1 (en) * | 2004-10-08 | 2019-08-28 | The Government of The United States of America as represented by The Secretary of The Department of Health and Human Services | Modulation of replicative fitness by using less frequently used synonymous codons |
US8168771B2 (en) | 2005-01-31 | 2012-05-01 | The Johns Hopkins University | Use of consensus sequence as vaccine antigen to enhance recognition of virulent viral variants |
US7863041B2 (en) | 2005-10-14 | 2011-01-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Rabies virus vector systems and compositions and methods thereof |
EP2402451B1 (en) | 2006-08-25 | 2018-03-21 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Method for stabilizing an DNA insert in a recombinant vaccinia vector |
CA2661808A1 (en) | 2006-08-29 | 2008-03-06 | Danisco Us, Inc., Genencor Division | Compositions and methods for improved protein production |
US20100041107A1 (en) | 2006-10-24 | 2010-02-18 | Basf Se | Method of reducing gene expression using modified codon usage |
HUE028873T2 (en) | 2006-10-24 | 2017-01-30 | Basf Se | A method for increasing gene expression using modified codon usage |
US8298541B2 (en) | 2007-03-29 | 2012-10-30 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Live attenuated virus vaccines for La Crosse virus and other Bunyaviridae |
BRPI0809600B1 (pt) * | 2007-03-30 | 2023-01-24 | The Research Foundation Of State University Of New York | Vírus atenuado útil para vacinas |
WO2009049350A1 (en) | 2007-10-15 | 2009-04-23 | The University Of Queensland | Expression system for modulating an immune response |
WO2017056094A1 (en) | 2015-09-30 | 2017-04-06 | Ramot At Tel-Aviv University Ltd. | Attenuated virus mutated at sites of evolutionarily conserved rna structure |
CA3020426A1 (en) | 2016-04-13 | 2017-10-19 | Synthetic Genomics, Inc. | Recombinant arterivirus replicon systems and uses thereof |
US11821111B2 (en) | 2019-11-15 | 2023-11-21 | Fred Hutchinson Cancer Center | Barcoded influenza viruses and deep mutational scanning libraries including the same |
-
2008
- 2008-03-31 BR BRPI0809600-7A patent/BRPI0809600B1/pt active IP Right Grant
- 2008-03-31 AU AU2008232491A patent/AU2008232491B2/en active Active
- 2008-03-31 HR HRP20181319TT patent/HRP20181319T4/hr unknown
- 2008-03-31 WO PCT/US2008/058952 patent/WO2008121992A2/en active Search and Examination
- 2008-03-31 EP EP08799746.6A patent/EP2139515B2/en active Active
- 2008-03-31 KR KR1020097022782A patent/KR101621100B1/ko active IP Right Grant
- 2008-03-31 DK DK08799746.6T patent/DK2139515T4/da active
- 2008-03-31 US US12/594,173 patent/US9476032B2/en active Active
- 2008-03-31 JP JP2010501289A patent/JP5733976B2/ja active Active
- 2008-03-31 CA CA2682089A patent/CA2682089C/en active Active
- 2008-03-31 PL PL08799746.6T patent/PL2139515T5/pl unknown
- 2008-03-31 EP EP23219605.5A patent/EP4368202A2/en active Pending
- 2008-03-31 MX MX2014010788A patent/MX349825B/es unknown
- 2008-03-31 CN CN200880018001.1A patent/CN103476425B/zh active Active
- 2008-03-31 EP EP18177156.9A patent/EP3431099B1/en active Active
- 2008-03-31 MX MX2009010549A patent/MX2009010549A/es active IP Right Grant
-
2014
- 2014-12-19 JP JP2014257141A patent/JP2015091247A/ja active Pending
-
2016
- 2016-09-07 US US15/258,584 patent/US10023845B2/en active Active
-
2018
- 2018-07-16 US US16/036,348 patent/US11162080B2/en active Active
-
2021
- 2021-10-28 US US17/513,032 patent/US20220298492A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0809600A2 (pt) | vírus atenuado útil para vacinas | |
DK3192874T3 (da) | Virusoprensning | |
DK2200646T3 (da) | RNA-Vacciner | |
ATE450271T1 (de) | Impfstoff | |
DK2049559T3 (da) | Forbedrede HPV vacciner | |
DK2114993T3 (da) | Vaccine | |
BR112012004807A2 (pt) | vacina para pcsk9 | |
DK2242752T3 (da) | Imidazolyl-biphenylimidazoler som hepatitis C-virus-inhibitorer | |
BRPI0919250A2 (pt) | métodos para a purificação de vírus | |
CR10571A (es) | Vacuna virica recombinante | |
BRPI0917205A2 (pt) | vacina polivalente | |
BRPI0909246A2 (pt) | Embalagens para artigos fumáveis | |
DK2043682T3 (da) | Influenzavaccine | |
BRPI0821034A2 (pt) | Vírus influenza modificado | |
BRPI0818354A2 (pt) | vacina preventiva do hiv baseada em anticorpos específicos para o hiv | |
BRPI0906946A2 (pt) | Vacinas baseadas em baculovírus | |
DK2152610T3 (da) | Dampindeslutning | |
BRPI1013597A2 (pt) | seringa para uso único | |
BRPI0921578A2 (pt) | vacinas unitemporais | |
BRPI0923034A2 (pt) | terapia de combinação para virus da hepatite c | |
BRPI0811114A2 (pt) | Andador para bebês | |
BRPI0919102A2 (pt) | vacinas de salmonella não-tifóide | |
ES1071355Y (es) | Dispositivo antisismico para edificios | |
ES1071762Y (es) | Soporte para reglas de albañileria | |
BRPI0922812A2 (pt) | antígeno recombinante para detecção de toxocaríase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B15I | Others concerning applications: loss of priority |
Free format text: PERDA DA PRIORIDADE US 61/068,666 DE 07/03/2008, CONFORME AS DISPOSICOES PREVISTAS NA LEI 9.279 DE 14/05/1996 (LPI) ART. 16 7O E NO ART. 28 DO ATO NORMATIVO 128/1997, POR NAO ATENDER AO DISPOSTO NO ART. 27 DO ATO NORMATIVO 128/1997, POIS NAO FOI APRESENTADA CESSAO DA REFERIDA PRIORIDADE, QUE POSSUI DEPOSITANTE DIFERENTE DO DEPOSITANTE DA FASE NACIONAL. |
|
B12F | Other appeals [chapter 12.6 patent gazette] | ||
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/03/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO. |